Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to -$1.6 million.

  • Utah Medical Products' Cash from Financing Activities rose 6663.28% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.1 million, marking a year-over-year decrease of 554.71%. This contributed to the annual value of -$23.8 million for FY2024, which is 47234.09% down from last year.
  • According to the latest figures from Q3 2025, Utah Medical Products' Cash from Financing Activities is -$1.6 million, which was up 6663.28% from -$4.5 million recorded in Q2 2025.
  • In the past 5 years, Utah Medical Products' Cash from Financing Activities registered a high of $19000.0 during Q1 2022, and its lowest value of -$8.1 million during Q4 2021.
  • For the 5-year period, Utah Medical Products' Cash from Financing Activities averaged around -$2.9 million, with its median value being -$1.1 million (2023).
  • In the last 5 years, Utah Medical Products' Cash from Financing Activities soared by 10200.21% in 2022 and then crashed by 562105.26% in 2023.
  • Quarter analysis of 5 years shows Utah Medical Products' Cash from Financing Activities stood at -$8.1 million in 2021, then surged by 88.6% to -$920000.0 in 2022, then decreased by 16.41% to -$1.1 million in 2023, then crashed by 623.34% to -$7.7 million in 2024, then surged by 78.82% to -$1.6 million in 2025.
  • Its last three reported values are -$1.6 million in Q3 2025, -$4.5 million for Q2 2025, and -$4.2 million during Q1 2025.